← All organizations

Nabriva Therapeutics AG

For profitContributed to NMEWebsite ↗

Also known as: NABRIVA | Nabriva Therapeutics | Nabriva Therapeutics AG

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Mar 1, 2022

Timeline

2000s

Jun 1, 2001
Nabriva Therapeutics AG— Founded

2010s

Jul 25, 2018
Zavante Therapeutics— Acquired
Aug 19, 2019
lefamulin— Marketing Organization
Aug 19, 2019
lefamulin— NDA Organization

Drugs by trial phase (8 distinct, 10 trials)

Phase 3 (3 own, 3 via acquisition)

Phase 2 (2 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

lefamulin

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Zavante Therapeutics

Recent trials (15)

NCT05225805Lead sponsorPhase 1Mar 1, 2022
NCT05111002CollaboratorPhase 1/Phase 2Nov 30, 2021
NCT03709914Lead sponsorPhase 1May 24, 2018
NCT03709914Study chairPhase 1May 24, 2018
NCT03709927Lead sponsorPhase 1Jan 11, 2018
NCT03131141Study directorPhase 1Jan 8, 2017
NCT03131141Lead sponsorPhase 1Jan 8, 2017
NCT02813694Study chairPhase 3Apr 1, 2016
NCT02813694Lead sponsorPhase 3Apr 1, 2016
NCT02559310Study chairPhase 3Sep 1, 2015
NCT02559310Lead sponsorPhase 3Sep 1, 2015
NCT02557789Lead sponsorPhase 1Jun 1, 2015
NCT02557789Study chairPhase 1Jun 1, 2015
NCT01119105Lead sponsorPhase 2May 1, 2010
NCT01119105Study chairPhase 2May 1, 2010

Details

Founded: Vienna, AT Jun 1, 2001
First NDA: Aug 19, 2019
Last known activity: Mar 1, 2022

Designations held

Fast track
Priority review